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Comparison of the clinical efficacy of medical treatment
of symptomatic benign prostatic hyperplasia between
normal and obese patients
Seung Hwan Lee1, Cheol Young Oh2, Kyung Kgi Park1, Mun Su Chung1, Se Jeong Yoo1 and Byung Ha Chung1
We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between
normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this
12-week prospective observational study, a total of 175 patients agedo40 years with International Prostate Symptom Scores (IPSS)
o12 points and prostate volumeo20 ml were prospectively enrolled. The patients were divided into two groups according to BMI or
WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4 mg once per day for 12 weeks. The
changes from baseline in the IPSS,maximal urinary flow rate (Qmax), post-void residual volume, quality of life (QoL) scores and adverse
events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients hadBMI.23 kgm22, and43
hadWC.90 cm.Obese patients represented byWC.90 cmorBMIo23 kgm22 had a significantly greater prostate volume compared
with non-obese patients at baseline. Total IPSS was significantly higher in the WC.90 cm group compared to the WCf90 cm group.
Total IPSSwas positively correlatedwith prostate volume (P50.031) andWC (P50.045). All groups showed significant improvements
in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. Themost
frequent AE was dizziness (n513), and it was significantly lower in the obese BPH patients. Obesity was associated with increased
prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in
obese men.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) and obesity are common in
older men and may greatly affect their quality of life. Furthermore,
epidemiological data demonstrate increasing prevalence of not only
LUTS secondary to benign prostatic hyperplasia (BPH) but also obes-
ity as men age.1,2 The Korean National Health and Nutrition Surveys
reported an increase in the prevalence of obesity in South Korea from
1995 to 2001 and an age-related increase in the prevalence of obesity in
Korean adults in 2001.3 The prevalence of clinical benign prostatic
hyperplasia was reported to be 10.6%–31% in men over 50 years of
age, with an age-related increase in South Korea.4,5 Positive associa-
tions between anthropometric measures of obesity and LUTS have
been observed in several studies.6–8 This association indicates that
modifiable risk factors may play a role in the pathogenesis of BPH.
We previously reported that the number of patients treated for BPH
is rapidly increasing in Korea, and, non-invasive medical therapy is
increasingly being chosen as the primary treatment option.9 Of the
medications for BPH, the doxazosin gastrointestinal therapeutic sys-
tem (GITS) has been effective and well tolerated as therapy for Korean
BPH patients with or without concomitant hypertension.10 Although
there are many studies concerning the clinical efficacy of doxazosin
GITS, there is a paucity of reports concerning the difference in efficacy
between normal and obese patients. In the present study, we aimed to
investigate the efficacy of doxazosin GITS in patients with BPH with
respect to body mass index (BMI) and waist circumference (WC).
MATERIALS AND METHODS
Study design
This was a 12-week prospective observational study conducted in our
institution, Yonsei University Health System from June 2009 to May
2010. Before initiating this study, approval was granted by the local
institutional review board, and patients provided informed consent.
Eligible patients with BPH/LUTS attending a urology clinic for the
first timewere enrolled. At the initial visit, height, weight andWCwere
measured in all enrolled patients. The signs of BPH were assessed
through the routine evaluation of BPH using transrectal ultrasound
of the prostate, maximal urinary flow rate (Qmax) assessed by uro-
flowmetry, post-void residual volume (PVR) assessed by ultrasound,
International Prostate Symptom Score (IPSS), urine analysis and
serum prostate-specific antigen (PSA) determination. The BMI of
each patient was calculated as the body weight in kilograms divided
by the square of the height in meters. After the initial evaluation,
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patients were assigned to receive doxazosin GITS at a dose of 4 mg
once per day for 12 weeks. During 4 and 12 weeks after medication
start all patients were evaluated via IPSS, uroflowmetry (Qmax) and
PVR. At each visit, adverse events (AEs) were recorded.
Patients
A total of 175 patients were prospectively enrolled in the study. All
patients were divided into two groups, normal BMI (n589, 23 kgm22
or less) and overweight or obese BMI (n586, 23 kg m-2 or above),
according to the Asia-Pacific obesity criteria.11 We also categorized
patients into two groups based on WC: normal waist (f90 cm) and
central obesity (.90 cm). The inclusion criteria were men 40 years of
age and older with a total IPSS of 12 or higher and a prostate volume
o20 ml as determined by transrectal ultrasound without any relevant
medical history or underlying comorbidities. Patients were excluded if
they had neurogenic bladder dysfunction, confirmed prostate cancer,
acute or chronic urinary retention status, acute or chronic prostatitis
within the previous 3 months, PSA levels .10 ng ml21, a history of
recurrent urinary tract infection or bladder stones, and previous trans-
urethral resection of the prostate or other surgical interventions
related to BPH. Of the 175 enrolled patients, 132 completed the study.
Forty-three discontinued the trial, of whom 17 were lost to follow-up,
6 discontinued because the drug was not effective and 17 experienced
AEs (e.g., dizziness or hypotension) (Figure 1).
Statistical analysis
The intent-to-treat population included all randomized patients who
took one or more doses of the study drug.
All data are presented as mean6s.e.m. and we analysed the data using
SPSS (version 12.0; Chicago, IL, USA). The changes from baseline in total
IPSS, quality of life (QoL) scores, Qmax and PVR were analysed using
paired Student’s t-tests. An independent t-test was used to compare data
between the normal and high-BMI or -WC groups. After performing a
covariate analysis of variance, adjusted for age and prostate volume, the
significance of the differences in total IPSS, QoL scores, Qmax and PVR
among groups based on baseline BMI and WC was examined using
ANCOVA with subsequent linear contrasts. Post hoc analysis com-
pared the mean changes from baseline to week 12 in total IPSS,
IPSS QoL scores, Qmax and PVR using a two-sided P value of ,0.05
to determine significance. The chi-square test was used to determine
the statistical significance of differences in AEs between the normal
BMI (n589, 23 kg m22 or less) and obese BMI (n586, 23 kg m22 or
above) groups or normal waist and central obesity groups. We used
linear regression to examine the prognostic factors for the improve-
ment of total IPSS. A P value of ,0.05 was considered significant.
RESULTS
Details about the patients enrolled are shown in Figure 1, and the
baseline clinical characteristics according to BMI or WC are summar-
ized in Table 1. The baseline data of the initially enrolled 175 patients
are balanced with that of the 132 patients who finished the study. Of
the 132 men who completed the study, 67 patients had a BMI above
23 kg m22, and 43 patients had a WC above 90 cm. The overall mean
age was 59.864.1 years, with a mean BMI of 21.763.5 kg m22 and a
mean WC of 79.9 cm. The mean total IPSS was 20.762.1, the mean
QoL score was 4.260.5 and the mean prostate volume was 32.365.1
ml. Obese patients represented by WC .90 cm (P50.026) or BMI
o23 kg m22 (P50.039) had a significantly greater prostate volume
compared with non-obese patients (Table 1). Total IPSS was signifi-
cantly higher in theWC.90 cm group compared to theWCf90 cm
group (22.4 versus 19.1, respectively). The serumPSA andQmax values
were significantly lower only in theWC.90 cm group (P,0.05). The
residual volumes were significantly higher in the WC .90 cm group
(P,0.05). In the regression analyses, after adjusting for age, total IPSS
was positively correlated with prostate volume (P50.031) and WC
(P50.045) (Table 2).
Figure 2 shows the changes in the total IPSS and QoL scores for
normal and obese patients after alpha-blocker medication (4 and 12
Figure 1 Details of subjects assigned to the study treatment. BMI, body mass index.
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weeks). All groups showed significant improvements in total IPSS and
QoL scores at 12 weeks. The mean changes in total IPSS from base-
line to 12 weeks were 29.3 (44.5%) and 28.1 (39.5%) points for the
high-BMI (P50.022) and low-BMI groups (P50.039), respectively,
and 29.8 (43.8%) and 27.4 (38.7%) points for the high-WC
(P50.027) and low-WC groups (P50.031), respectively. Compared
with the non-obese men, the high-BMI and high-WC groups showed
greater reductions in total IPSS at week 12 (P50.034 and P50.021,
respectively). Improvement of the QoL score was not different among
groups; all groups showed improvements in QoL at 12 weeks. In the
linear regression analysis, the change in the total IPSS between baseline
and week 12 following alpha-blocker medication was positively cor-
related with baseline WC (P50.028).
Qmax significantly improved at week 12 (12.3 ml s
21) only in the
high-WC group. The high-BMI group had a greater reduction in PVR
(223.1 ml) from baseline compared to the other groups at week 12. In
all, 17 treatment-related AEs were reported (12.9%). The most fre-
quent AE was dizziness, reported by 13 patients (9.8%). Other AEs
were postural hypotension (two, 1.5%), gastrointestinal disorder (one
patient with gastritis, 0.7%) and prostatic disorder (one patient with
aggravation of chronic perineal discomfort, 0.7%). Dizziness was sig-
nificantly higher in the low-BMI group (n59, 10.1%) compared with
the high-BMI group (n54, 4.7%, P50.042).
DISCUSSION
Our data demonstrate that the total IPSS was positively correlated with
central obesity, as represented by waist circumference and prostate
volume. Lee et al.12 found that centrally obese men had lower testoster-
one concentrations and greater prostate volumes. Obesity raises
oestrogen levels and free and total estradiol concentrations, while low-
ering free and total testosterone and serum globulin-binding protein
levels.13 Greater oestrogen levels in the environment of age- and obes-
ity-induced lower testosterone levels may affect prostate cell growth.
However, the extent to which obesity may influence BPH according to
sex steroid hormones should be further investigated.
McVary et al.14 demonstrated that increased sympathetic tone (auto-
nomic hyperactivity) can result in LUTS and subjective voiding com-
plaints. In particular, abdominal obesity increases the oestrogen-
to-androgen ratio and may increase sympathetic nervous activity, both
of which are known to influence the development of BPH and the
severity of LUTS.15 Among the indices of overweight and body adipose
tissue distribution, it is visceral adiposity that is most closely related with
Table 1 Baseline characteristics of study subjects according to waist circumference and BMI
Waist circumferencef90 cm Waist circumference .90 cm BMI ,23.0 kg m22: normal BMIo23.0 kg m22: obese
No. 109 66 89 86
Age (years) 60.062.9 59.564.0 60.363.1 59.364.8
Prostate volume (ml) 32.7611.4 36.369.2a 32.3610.1 35.669.7d
PSA (ng ml21) 2.1461.9 1.7361.5b 1.9961.1 2.0960.7
Total IPSS 19.166.9 22.465.3b 20.567.6 20.967.2
Voiding symptom subscore 12.661.0 13.961.4 12.561.1 13.361.0
Storage symptom subscores 7.560.8 8.460.7 8.060.4 7.560.6
QoL score 4.260.4 4.460.4 4.260.4 4.260.3
Qmax (ml s
21) 14.161.7 11.763.9a 13.962.2 13.362.5
Residual volume (ml) 33.5611.7 51.5619.1c 32.9612.1 37.8610.9
Abbreviations: BMI, body mass index; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen; Qmax, maximal urinary flow rate; QoL, quality of life.
The values for prostate volume, PSA, IPSS, QoL and Qmax are expressed as mean6s.e.m.
By Student’s t-test.
aP50.026, bP50.044, cP50.033, compared with WCf90 cm;
dP50.039, compared with BMI,23.0 kg m-2.
The baseline data of the initially enrolled 175 patients are balanced with that of the 132 patients who finished the study.
Table 2 Linear regression analyses evaluating factors correlated with
total IPSS
Coefficient P value
BMI (kg m22) 0.230 0.133
Waist circumference (cm) 0.295 0.045
Prostate volume (ml) 0.327 0.031
Qmax (ml s
21) 0.194 0.209
Residual volume (ml) 0.206 0.195
PSA (ng ml21) 0.163 0.492
Abbreviations: BMI, body mass index; IPSS, International Prostate Symptom Score;
PSA, prostate-specific antigen; Qmax, maximal urinary flow rate.
Component is continuous variable.
Figure 2 Percentage improvement in total IPSS (a) and QoL scores (b) from
baseline (0 week) by visit (4 and 12 weeks) according to BMI and WC. BMI, body
mass index; IPSS, International Prostate Symptom Score; QoL, quality of life; WC,
waist circumference.
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sympathetic overactivity. Among the obese patients, the whole body
norepinephrine spillover rate is quantitatively linked to waist circumfer-
ence.16 Sympathetic nerve firing rates measured by microneurography
have been reported to be 55% higher in men with elevated abdominal
visceral fat levels than in men with only subcutaneous obesity. This
increased sympathetic activity in centrally obese men is involved in
LUTS/BPH, with norepinephrine and alpha1-adrenoceptors represent-
ing a common link.17,18
Interestingly, we observed significantly greater improvement in the
mean change in total IPSS from baseline to week 12 in the high-BMI
and -WC groups, even though the low BMI or low WC groups also
showed significant improvements at week 12. Furthermore, the cent-
rally obese BPH/LUTS patients showed significant improvement in
Qmax following alpha-blocker medication at week 12. Obesity is char-
acterized by enlarged depots of adipose tissue, which are metabolically
active and secrete numerous hormones and proteins that influence local
adipocyte biology as well as distant organ systems.19,20 Leptin and
tumor-necrosis factor-alpha are hormones secreted from adipose tissue
that affect the ingestion of food and body weight.21 It is also known that
leptin stimulates the cellular proliferation of BPH.22 Ueshiba and
Miyachi23 reported that treatment with the doxazosin improved dysli-
pidemia in obesity patients. Furthermore, circulating tumor-necrosis
factor-alpha and leptin levels decreased significantly within 3 months of
doxazosin treatment.23 Therefore, doxazosin GITS might have a bene-
ficial effect on adipose endocrine activity in obese patients with BPH.
We previously reported that individuals with more severe IPSS and
larger prostate volumes have a higher risk ofmedical treatment failure,
a result that is partially in conflict with the current results.24 However,
in that report we did not include the anthropometric parameters of
BPH patients, and we included BPHpatients taking 5-alpha-reductase
inhibitors. Our results suggest that the effectiveness of alpha-blocker
therapy is more complicated and that other factors should be further
evaluated in addition to the parameters related to BPH or the clinical
pharmacokinetics of doxazosin GITS. In addition, in our study we
could not identify significant prognostic factors of non-response to
doxazosin GITS due to the limited number of medical treatment fail-
ures. Therefore, further study based on a large sample size is needed to
elucidate these factors.
This trial should be interpreted within the context of its limitations.
It has a relatively short follow-up period and a small sample size
despite being a prospective study.However, considering the increasing
prevalence of concomitant comorbidities (e.g., hypertension and dia-
betes mellitus), the size of our sample of patients without any relevant
medical history or underlying comorbidities might be adequate to
determine statistical significance.
In our study, obesity was associated with increased prostate volume
and lower urinary tract symptoms in BPH patients. Doxazosin GITS
appears to be safe and efficacious for controlling symptoms, especially
in obese men with BPH.
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